The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Peptide-based inhibitors for cancer treatment. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity. 

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have. 

110 innovations will shape the pharmaceutical industry 

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry. 

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry. 

Innovation S-curve for the pharmaceutical industry 

Peptide-based inhibitors  are a key innovation area for cancer treatment

Peptide-based inhibitors penetrate tumours/tissues and their chemical modifications and production facilitate improved stability and pharmacokinetics. In comparison to proteins and antibodies, peptides are simpler to synthesise in various cells, can be coupled to a variety of substances, and can be modified in a variety of ways. Peptides have a longer shelf life due to their simplicity and ease of transport. As molecular targeting peptides, anti-cancer peptides penetrate the plasma membrane, nuclear membrane, and mitochondrial membrane of cancer cells, exerting pharmacological activity through various mechanisms (such as inhibiting DNA synthesis and cell division), thus causing apoptosis of cancer cells.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 80+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of peptide-based inhibitors for cancer treatment.

Key players in peptide-based inhibitors for cancer treatment – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to peptide-based inhibitors for cancer treatment

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Seagen 330 Unlock Company Profile
Takeda Pharmaceutical 245 Unlock Company Profile
Immatics 233 Unlock Company Profile
Ambrx Biopharma 112 Unlock Company Profile
Agios Pharmaceuticals 87 Unlock Company Profile
Pierre Fabre Foundation 82 Unlock Company Profile
Pfizer 67 Unlock Company Profile
E. Merck 66 Unlock Company Profile
Kalvista Pharmaceuticals 52 Unlock Company Profile
Zymeworks 51 Unlock Company Profile
Amunix Operating 47 Unlock Company Profile
Gilead Sciences 46 Unlock Company Profile
Mersana Therapeutics 44 Unlock Company Profile
Bayer 41 Unlock Company Profile
Vertex Pharmaceuticals 38 Unlock Company Profile
Bicycle Therapeutics 36 Unlock Company Profile
AltruBio 36 Unlock Company Profile
German Cancer Research Center 35 Unlock Company Profile
Protagonist Therapeutics 33 Unlock Company Profile
Jiangsu Hengrui Medicine 33 Unlock Company Profile
Amgen 32 Unlock Company Profile
Cara Therapeutics 32 Unlock Company Profile
Eurofins Scientific 30 Unlock Company Profile
Capgemini 29 Unlock Company Profile
CytRx 28 Unlock Company Profile
NeoStrata Company 28 Unlock Company Profile
Sutro Biopharma 27 Unlock Company Profile
Onxeo 23 Unlock Company Profile
Aeterna Zentaris 22 Unlock Company Profile
Oncopeptides 20 Unlock Company Profile
Ipsen 20 Unlock Company Profile
Sumitomo Chemical 19 Unlock Company Profile
Pharma Mar 19 Unlock Company Profile
Aileron Therapeutics 19 Unlock Company Profile
Sichuan Kelun Industrial Group 16 Unlock Company Profile
UK Research and Innovation 16 Unlock Company Profile
Heidelberg Pharma 16 Unlock Company Profile
MabPlex International 15 Unlock Company Profile
Lytix Biopharma 15 Unlock Company Profile
Cypralis 15 Unlock Company Profile
Bristol-Myers Squibb 14 Unlock Company Profile
Sirona Biochem 13 Unlock Company Profile
Joyant Pharmaceuticals 13 Unlock Company Profile
Celltrion 13 Unlock Company Profile
IDP Discovery Pharma 12 Unlock Company Profile
Astellas Pharma 12 Unlock Company Profile
OliPass 12 Unlock Company Profile
3D Medicines 12 Unlock Company Profile
Sutura Therapeutics 11 Unlock Company Profile
Zentaris 10 Unlock Company Profile

Source: GlobalData Patent Analytics

Seagen is the leading patent filer in peptide-based inhibitors for cancer treatment. Seagen, formerly Seattle Genetics, develops and markets monoclonal antibody-based therapies for the treatment of cancer. Seagen’s products are based on its ADC and SEA technology, which focuses on the identification of monoclonal antibodies. The company sells its products through specialty distributors, with its headquarters being in Bothell, Washington, US. Besides Seagen, Takeda Pharmaceutical and Immatics are the other key patent filers of peptide-based inhibitors for the treatment of cancer.

In terms of application diversity, Ascentawits Pharmaceuticals is the top company, followed by OBI Pharma and Mabwell Shanghai Bioscience. By means of geographic reach, Onxeo holds the top position. Whilst Gilead Sciences and the German Cancer Research Center are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.